Answers are grounded in this paper and cite their sources.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor that is used for hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative, PI3KCA mutated metastatic breast cancer. Clinical trials have shown promise in HER2-positive patients as well. It is a novel targeted chemotherapeutic agent that has been commonly associated with side effects like hyperglycemia, rash, diarrhea, and elevation in serum aminotransferases. A literature search of 3 databases (PubMed, Clinical Key, Google Scholar) did not reveal a single case documenting alpelisib-induced acute cholestatic hepatitis. Diagnosis is one of exclusion and withdrawal of the offending agent is the principal treatment. Our case identifies a severe adverse event of intrahepatic cholestatic hepatitis induced by alpelisib in a patient with HR+, HER2+, PI3KCA mutated metastatic breast cancer She was receiving exemestane 25 mg/day and trastuzumab 6mg/kg q3wk for 8 years and apelisib 150 mg/day for 8 months. Laboratory results indicated significant transaminitis. Trastuzumab and alpelisib were held at admission. An extensive workup including liver biopsy was done which revealed findings consistent with acute drug-induced hepatitis with clinical findings suggestive of alpelisib-induced intrahepatic cholestasis.
No takes yet. Share an insight, caveat, or question.
Ashraf et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: